Acton Pharmaceuticals, Sanofi sales and marketing update

Sanofi granted Acton exclusive development and commercialization rights to Nasacort HFA triamcinolone acetonide in the U.S. to treat nasal allergy symptoms. The once-daily product is an intranasal corticosteroid dry-aerosol formulation that contains hydrofluoroalkane (HFA). Sanofi retains all rights to water-based spray Nasacort AQ. Terms were not disclosed. ...